BlueRock Therapeutics is a next-generation regenerative medicine company focused on breakthrough treatments and new horizons in medicine. BlueRock Therapeutics’ platform is based on state of the art pluripotent stem cell engineering tools and expansion technology. The company represents a strategic partnership between Bayer and Versant Ventures, and has been granted access to one of the largest-ever Series A financings in biotech. Our vision at BlueRock is to cure cardiovascular, neurologic and other diseases with significant unmet need and diminished self-repair potential. Our platform is enabled by strategic partnerships with a number of leading academic and industry collaborators in the U.S., Canada and Japan.